TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12413616
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg followed by misoprostol 800 microg vaginally on the same day
Study: 2878457
Drug: 0.54 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.54 g/kg ethanol
Study: 2878457
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg ethanol
Study: 24670314
Drug: NMES intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NMES intervention followed by conventional treatment (thermaltactile stimulation with intensive repetition of a dry-swallow task)
Study: 24670314
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without NMES
Study: 21034484
Drug: Histamine-2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine-2-receptor antagonists (H2RA)
Study: 8136599
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine solution
Study: 18326251
Drug: 0.2% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% ropivacaine solution
Study: 12410512
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (5-25 ml) for local anesthesia of the groin
Study: 10220626
Drug: Lidocaine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (4 boluses of 50 mg each every 2 minutes, then an infusion of 3 mg/min for 12 hours, then 2 mg/min for 36 hours)
Study: 7016629
Drug: Budesonide 0.025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.025% ointment
Study: 7016629
Drug: Budesonide 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.01% ointment (maintenance treatment)
Study: 7016629
Drug: Betamethasone-17-valerate 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone-17-valerate 0.1% ointment
Study: 19562253
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of methylprednisolone pre-operatively
Study: 25609939
Drug: Acetylcholinesterase inhibitors
Normalized name: acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcholinesterase inhibitors (AChEIs)
Study: 17415706
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory compounds (rofecoxib)
Study: 17415706
Drug: Sex steroid
Normalized name: Sex steroid binding globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroid hormones (testosterone, estrogens)
Study: 15557906
Drug: Heparin-bonded Dacron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded Dacron (HBD)
Study: 22990217
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine gum
Study: 2626520
Drug: Oral fluphenazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluphenazine (FLU)
Study: 769555
Drug: Aspirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (600 mg every 6 hours)
Study: 20610466
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication adherence
Study: 29991214
Drug: Sports therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports therapy and recreation exercise program
Study: 19692798
Drug: GW406381 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 25 mg
Study: 19099009
Drug: GW406381 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 50 mg
Study: 17876866
Drug: Bimosiamose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimosiamose disodium 100 mg
Study: 17876866
Drug: Bimosiamose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimosiamose disodium 200 mg
Study: 17876866
Drug: Bimosiamose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimosiamose disodium 300 mg
Study: 15497369
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (20,000 IU of beta-carotene, 400 IU alpha-tocopherol acetate, 500 mg ascorbic acid, 100 microg selenium, and 30 mg zinc)
Study: 30086256
Drug: Topical pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical pentoxifylline (PTX) 5% ointment, applied twice daily for 14 days
Study: 19324483
Drug: Intravenous EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous EPO administration
Study: 19324483
Drug: Subcutaneous EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous EPO administration
Study: 16964676
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg once daily for 48 weeks
Study: 11111818
Drug: Prosorba Immunoadsorption
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prosorba Immunoadsorption Column treatment (active treatment arm)
Study: 11111818
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment (apheresis only, control arm)
Study: 9616826
Drug: Pristinamycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pristinamycin (1 g bid for 10-14 days)
Study: 9616826
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (500 mg q.i.d. for 10-14 days)
Study: 1570887
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 12.5 mg hyperbaric 0.5% bupivacaine and postoperative immobilisation for either 6 or 24 hours.
Study: 30677181
Drug: Anti-osteoporotic medications
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-osteoporotic medications
Study: 24578135
Drug: Phosphate binder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate binder therapy
Study: 18839400
Drug: Generalized Anxiety
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized Anxiety Disorder Severity Scale (GADSS) administered via telephone
Study: 17442467
Drug: Pnc polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pnc polysaccharide vaccine, Hemophilus influenzae type b conjugate vaccine, and tetanus toxoid
Study: 15921829
Drug: MC-4 vaccine
Normalized name: Adenovirus Type 4 Vaccine Live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-4 vaccine
Study: 15194828
Drug: MPS-4 vaccine
Normalized name: Adenovirus Type 4 Vaccine Live
DrugBank: Human adenovirus e serotype 4 strain cl-68578 antigen (DB14409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPS-4 vaccine
Study: 15194828
Drug: Higher avidity
Normalized name: AVID-200
DrugBank: AVID-200 (DB18454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher avidity antibody
Study: 11115819
Drug: Oral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral glutamine (18 g/day)
Study: 8119688
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodeoxycholic acid (13 to 15 mg/kg/day)
Study: 27706121
Drug: Sensory Integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integration Therapy (SIT) for 2 weeks, 5 times a week
Study: 31787369
Drug: Methylcobalamin 500
Normalized name: methylcobalamin 500 mcg oral lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcobalamin 500 μg and folic acid 400 μg once daily
Study: 27832260
Drug: Intravaginal testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal testosterone cream (IVT)
Study: 27832260
Drug: Estradiol vaginal
Normalized name: Estradiol Vaginal
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol vaginal ring (7.5 μg/d)
Study: 9869282
Drug: Overdenture supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture supported by two IMZ implants (group A)
Study: 9869282
Drug: Overdenture supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overdenture supported by four IMZ implants (group B)
Study: 10841968
Drug: Salbutamol (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (8 mg slow-release, twice daily for 3 weeks)
Study: 8396841
Drug: Oral estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estriol (3 mg/day for 4 weeks followed by 2 mg/day for a further 6 weeks)
Study: 25939582
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (Cool Kids CBT program)
Study: 14503056
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus Tongxinluo (TXL) Capsule
Study: 11018096
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens from phase II studies with expected power of 0.62 and 0.58
Study: 11018096
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens from six other phase II studies
Study: 3003020
Drug: Atenolol, 50
Normalized name: Atenolol, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol, 50 mg once/day
Study: 3003020
Drug: ICI 118551,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118551, 20 mg 3 times/day
Study: 22463944
Drug: Herbal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal treatment
Study: 20144188
Drug: Patient-guided focussed
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-guided focussed medium-energy density ESWT treatments (3 sessions at weekly intervals)
Study: 16167962
Drug: 6 hours
Normalized name: nitroglycerin 0.6 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hours administration of misoprostol
Study: 16167962
Drug: 36-48 hours
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 36-48 hours administration of misoprostol
Study: 12870373
Drug: Magnesium flush
Normalized name: T8 Keto Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium flush infusion into the aortic root before cross-clamp removal
Study: 12870373
Drug: Placebo flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo flush infusion into the aortic root before cross-clamp removal
Study: 10385632
Drug: UDCA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA therapy (600 mg/d)
Study: 8874423
Drug: One-ring treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-ring treatment group (17 eyes)
Study: 8874423
Drug: Two-ring treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-ring treatment group (8 eyes)
Study: 1997518
Drug: Bromocriptine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (5 mg/day in trial I; 7.5-10 mg/day in trial II)
Study: 31446992
Drug: Afatinib starting
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib starting dose of 20 mg/day, with potential increase in 10 mg increments up to 50 mg/day
Study: 26844688
Drug: Vitamin-D and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-D and calcium replacement (800 IU Vitamin-D and 500 mg Calcium once daily)
Study: 22008377
Drug: Zopiclone 5
Normalized name: zopiclone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 5 or 10 mg
Study: 22008377
Drug: Ethanol 50
Normalized name: ethanol 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 50 g
Study: 17258104
Drug: Structured nursing
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured nursing intervention program including music therapy, drama, and group therapy
Study: 12825865
Drug: Regular dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular dose of omeprazole (20 mg/day for 3 days)
Study: 12825865
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of omeprazole (80 mg bolus + 8 mg/h infusion/day for 3 days)
Study: 10806604
Drug: Tenecteplase (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (30, 40, or 50 mg intravenous bolus)
Study: 10806604
Drug: Alteplase (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (100 mg intravenous as accelerated 90-minute infusion)
Study: 10806604
Drug: Tenecteplase (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (approximately 0.5 mg/kg)
Study: 7639163
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg verapamil
Study: 7639163
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg verapamil
Study: 7639163
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg verapamil
Study: 7639163
Drug: 540 mg
Normalized name: lecithin 540 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 540 mg verapamil
Study: 6679514
Drug: Lisuride (0.0250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (0.0250 mg single oral dose)
Study: 30839426
Drug: Positive treatment-related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive treatment-related suggestions
Study: 28552083
Drug: Maudsley Model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maudsley Model Anorexia Nervosa Treatment for Adults
Study: 28552083
Drug: Enhanced Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Cognitive Behavioural Therapy
Study: 26316741
Drug: Olodaterol 2
Normalized name: OLODATEROL 2.5MCG/ACTUAT 14D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olodaterol 2 µg
Study: 26316741
Drug: Olodaterol 5
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 5 µg
Study: 26316741
Drug: Olodaterol 10
Normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olodaterol 10 µg
Study: 23159168
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment in conjunction with orthognathic surgery
Study: 22951790
Drug: 380 mg
Normalized name: aspirin 380 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 380 mg XR‐NTX
Study: 19624833
Drug: Face-to-face group
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face group treatment programme
Study: 16121931
Drug: Mitherapist (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitherapist (15 mg/dl Lentinan, particulate size of 0.2 microm)
Study: 31953790
Drug: Diroximel fumarate
Normalized name: Diroximel fumarate
DrugBank: Diroximel fumarate (DB14783)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Diroximel fumarate (DRF) 462 mg
Study: 24888488
Drug: Siltuximab 15
Normalized name: Siltuximab
DrugBank: Siltuximab (DB09036)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Siltuximab 15 mg/kg every 4 weeks + best supportive care (BSC)
Study: 22356258
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg (partial responders adjusted to dosing every 8 weeks)
Study: 22356258
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg (partial responders adjusted to dosing every 8 weeks)
Study: 20530973
Drug: Epirubicin followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF: Epirubicin 100 mg/m² on day 1, CMF: 600 mg/m² cyclophosphamide, 40 mg/m² methotrexate, 600 mg/m² 5-fluorouracil on days 1 and 8)
Study: 20530973
Drug: Paclitaxel followed
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel followed by epirubicin and vinorelbine (T-EV: Paclitaxel 175 mg/m² on day 1, Epirubicin 75 mg/m² on day 1, Vinorelbine 25 mg/m² on days 1 and 8)
Study: 16485513
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/day for the first month and 8 mg/day for the remaining 11 months)
Study: 11920300
Drug: Combination B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination B vaccine (recombinant Plasmodium falciparum ring‐infected erythrocyte surface antigen and 2 merozoite surface proteins (MSP1 and MSP2) formulated in oil‐based adjuvant)
Study: 10325814
Drug: Trophic feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophic feeding (0.5 ml/h if birthweight < 1 kg, 1 ml/h if ≥ 1 kg) in addition to parenteral nutrition
Study: 10421395
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition alone
Study: 31572236
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride
Study: 25710276
Drug: Topical BAK-preserved
Normalized name: benzalkonium Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical BAK-preserved tafluprost
Study: 21570522
Drug: 1 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/d n3-PUFA
Study: 21570522
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d n3-PUFA
Study: 19770175
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy home program (OTHP) for 8 weeks
Study: 19770175
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy home program (OTHP) for 4 weeks (continued for 8 weeks)
Study: 19770175
Drug: No occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: No occupational therapy home program (no OTHP)
Study: 15580811
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg vitamin C, 800 mg vitamin E, and 10 mg folate
Study: 9740162
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at 0.2 IU/kg/d subcutaneously for 4 weeks
Study: 9740162
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dietary prescriptions only)
Study: 7989939
Drug: Chemotherapy (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (adjuvant fluorouracil (5-FU)-based)
Study: 25533572
Drug: Follow-up observation
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up observation (no treatment)
Study: 22959395
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose multidetector computed tomography coronary angiography (MDCT)
Study: 21982664
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) 150 mg
Study: 21982664
Drug: Anacetrapib (ANA)
Normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (ANA) 300 mg
Study: 21982664
Drug: Atorvastatin (ATV)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (ATV) 20 mg with Anacetrapib
Study: 18652550
Drug: Intradermal trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal trivalent inactivated influenza vaccine (15 or 21 microg of hemagglutinin per strain)
Study: 20372053
Drug: Intramuscular control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular control vaccine
Study: 31925721
Drug: Duloxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (60 mg daily)
Study: 12709465
Drug: COER verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER verapamil (180 mg)
Study: 12709465
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg) or Hydrochlorothiazide (12.5 mg)
Study: 3003298
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 25 mg orally
Study: 3003298
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) + Naloxone (NAL) 0.4 mg bolus followed by 4.0 mg/h infusion
Study: 29045820
Drug: 5-fluorouracil cream
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil cream
Study: 29045820
Drug: methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methyl aminolevulinate photodynamic therapy (MAL-PDT)
Study: 26718237
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus medication
Study: 24317794
Drug: Baseline subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline subcutaneous adiposity
Study: 23090987
Drug: Dasatinib (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib (100-200 mg daily) + CCNU (90-110 mg/m2)
Study: 20606413
Drug: Continuous erythropoietin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous erythropoietin receptor activator (CERA) once monthly
Study: 20606413
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta therapy
Study: 7644052
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 mg qid)
Study: 2693431
Drug: Individualized pharmacokinetic
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized pharmacokinetic (PK) dosing of amikacin
Study: 2693431
Drug: Standard (every
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard (every 12 h) dosing of amikacin
Study: 681132
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg thioridazine